|
Testosterone and Growth Hormone for Bone Loss in Men Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Testosterone and Growth Hormone for Bone Loss in Men conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Testosterone and Growth Hormone for Bone Loss in Men Clinical research trials and Testosterone and Growth Hormone for Bone Loss in Men health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Testosterone and Growth Hormone for Bone Loss in Men. Testosterone and Growth Hormone for Bone Loss in Men Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Testosterone and Growth Hormone for Bone Loss in Men clinical trial. Test subjects typically receive the most expert healthcare available for their Testosterone and Growth Hormone for Bone Loss in Men condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Testosterone and Growth Hormone for Bone Loss in Men  Testosterone and Growth Hormone for Bone Loss in Men
Testosterone and Growth Hormone for Bone Loss in Men
For Condition: Hypopituitarism,Hypogonadism,Growth Hormone Deficiency
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structure more than testosterone treatment alone.
Details: Replacement of testosterone or growth hormone in patients who are deficient improves osteoporosis associated with these defiencies. In some tissues, such as muscle, the effects of testosterone and growth hormone are additive, but it is not known if the effects are additive in bone as well. This study will compare the effects of testosterone alone with testosterone plus growth hormone in improving bone structure in men with total pituitary hormone deficiency. Participants in this study will be men who have pituitary or hypothalamic disease and have deficiencies of all pituitary hormones, but who have not been treated with either testosterone or growth hormone. The men will be randomly assigned to receive either testosterone alone or testosterone plus growth hormone for two years. Testosterone in a gel form will be applied daily to the skin. Growth hormone will be self-administered by daily subcutaneous injection. Blood concentrations of both hormones will be monitored with blood tests every 3 months during the 2 year study. Doses of the hormones will be adjusted to keep blood concentrations of the hormones within the normal range. Changes in bone structure will be assessed noninvasively before treatment and after one year and two years of treatment by magnetic resonance microimaging (µMRI) and dual energy X-ray absorptiometry (DEXA).
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria: Inclusion Criteria: - Documented hypothalamic or pituitary hormone deficiency - Testosterone deficiency, defined as two morning readings of total serum testosterone less than 250 ng/dL within 1 month of study entry - Growth hormone deficiency with cortisol and/or thyroxine deficiencies AND serum IGF-1 less than age-specific normal or growth hormone peak response to arginine-GHRH stimulus less than 4.6 ng/ml - Duration of testosterone and growth hormone deficiencies of two years or more - Stable replacement of cortisol and/or thyroxine deficiencies for a year or more - Able to give informed consent Exclusion Criteria: - Current testosterone treatment or treatment during the two years prior to study entry - Current growth hormone treatment or treatment during the two years prior to study entry - Use of other prescription or over-the-counter androgens (androstenedione, DHEA), estrogens, or antiandrogens (spironolactone, ketoconazole) - Diseases that could influence bone, such as hyperparathyroidism - Medications that could influence bone, such as anticonvulsants or glucocorticoids (prednisone greater than 20 mg/day for longer than 2 weeks/year). Calcium and over-the-counter vitamin D supplements are allowed. - Cancer that could limit life expectancy to fewer than 5 years - Neuromuscular disease or history of stroke with residual neurological defect - Severe or uncontrolled psychiatric illness or dementia - Noncancerous enlargement of the prostate gland (American Urological Association symptom score greater than 21) - Prostate cancer by history, prostate nodule on digital rectal exam (DRE), or prostate specific antigen (PSA) greater than 4 - Current alcohol or drug dependence - Heart failure (New York class III or IV) - Unstable angina - Myocardial infarction within 3 months of study entry - Liver disease (ALT greater than 3 x normal) - Renal disease (serum creatinine greater than 2.5 mg/dl) - Diabetes mellitus (glycosolated hemoglobin greater than 8.0%) - Hypertension (systolic BP greater than 160 or diastolic BP greater than 100 mm Hg) - Hematocrit greater than 48% - Body mass index (BMI) greater than 32 - Untreated, severe, obstructive sleep apnea (Epworth sleepiness score greater than 10) - Unable to undergo an MRI because of a cardiac pacemaker or ferrometallic objects in the body
Total Enrollment: 40
Location and Contact Information:
Overall Study Official:
PeterSnyder, Principal Investigator, University of Pennsylvania
Hospital of the University of Pennsylvania *Recruiting*
Philadelphia, Pennsylvania, 19104
United States
Recruiting Helen Peachey 215-898-5664
Additional Information:
Study ID Numbers: NIAMS-118; RO1 AR050618-01
Study Start Date: March 2004
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080483
Other Hypogonadism Studies:
1. Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency
2. Study of Pituitary Size and Function in Familial Dwarfism of Sindh
3. Testosterone and Growth Hormone for Bone Loss in Men
Related Studies:
Other Hypogonadism Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Testosterone and Growth Hormone for Bone Loss in Men
|
|
|
|
|
|
|
|
